BACKGROUND: Although the incidence of cannabis abuse/dependence in Americans is rising, the neurobiology of cannabis addiction is not well understood. Imaging studies have demonstrated deficits in striatal D(2)/D(3) receptor availability in several substance-dependent populations. However, this has not been studied in currently using chronic cannabis users. OBJECTIVE: The purpose of this study was to compare striatal D(2)/D(3) receptor availability between currently using chronic cannabis users and healthy controls. METHODS: Eighteen right-handed males age 18-34 were studied. Ten subjects were chronic cannabis users; eight were demographically matched controls. Subjects underwent a [(11)C]raclopride (RAC) PET scan. Striatal RAC binding potential (BP(ND)) was calculated on a voxel-wise basis. Prior to scanning, urine samples were obtained from cannabis users for quantification of urine Δ-9-tetrahydrocannabinol (THC) and THC metabolites (11-nor-Δ-9-THC-9-carboxylic acid; THC-COOH and 11-hydroxy-THC;OH-THC). RESULTS: There were no differences in D(2)/D(3) receptor availability between cannabis users and controls. Voxel-wise analyses revealed that RAC BP(ND) values were negatively associated with both urine levels of cannabis metabolites and self-report of recent cannabis consumption. CONCLUSIONS: In this sample, current cannabis use was not associated with deficits in striatal D(2)/D(3) receptor availability. There was an inverse relationship between chronic cannabis use and striatal RAC BP(ND). Additional studies are needed to identify the neurochemical consequences of chronic cannabis use on the dopamine system.
BACKGROUND: Although the incidence of cannabis abuse/dependence in Americans is rising, the neurobiology of cannabis addiction is not well understood. Imaging studies have demonstrated deficits in striatal D(2)/D(3) receptor availability in several substance-dependent populations. However, this has not been studied in currently using chronic cannabis users. OBJECTIVE: The purpose of this study was to compare striatal D(2)/D(3) receptor availability between currently using chronic cannabis users and healthy controls. METHODS: Eighteen right-handed males age 18-34 were studied. Ten subjects were chronic cannabis users; eight were demographically matched controls. Subjects underwent a [(11)C]raclopride (RAC) PET scan. Striatal RAC binding potential (BP(ND)) was calculated on a voxel-wise basis. Prior to scanning, urine samples were obtained from cannabis users for quantification of urine Δ-9-tetrahydrocannabinol (THC) and THC metabolites (11-nor-Δ-9-THC-9-carboxylic acid; THC-COOH and 11-hydroxy-THC;OH-THC). RESULTS: There were no differences in D(2)/D(3) receptor availability between cannabis users and controls. Voxel-wise analyses revealed that RAC BP(ND) values were negatively associated with both urine levels of cannabis metabolites and self-report of recent cannabis consumption. CONCLUSIONS: In this sample, current cannabis use was not associated with deficits in striatal D(2)/D(3) receptor availability. There was an inverse relationship between chronic cannabis use and striatal RAC BP(ND). Additional studies are needed to identify the neurochemical consequences of chronic cannabis use on the dopamine system.
Authors: Christopher S Kearn; Katherine Blake-Palmer; Emma Daniel; Ken Mackie; Michelle Glass Journal: Mol Pharmacol Date: 2005-02-14 Impact factor: 4.436
Authors: F Picard; D Bruel; D Servent; W Saba; C Fruchart-Gaillard; M-A Schöllhorn-Peyronneau; D Roumenov; E Brodtkorb; S Zuberi; A Gambardella; B Steinborn; A Hufnagel; H Valette; M Bottlaender Journal: Brain Date: 2006-06-30 Impact factor: 13.501
Authors: Patrick D Skosnik; Giri P Krishnan; Erin E Aydt; Heidi A Kuhlenshmidt; Brian F O'Donnell Journal: Am J Psychiatry Date: 2006-10 Impact factor: 18.112
Authors: Michael A Nader; Drake Morgan; H Donald Gage; Susan H Nader; Tonya L Calhoun; Nancy Buchheimer; Richard Ehrenkaufer; Robert H Mach Journal: Nat Neurosci Date: 2006-07-09 Impact factor: 24.884
Authors: Scott K Ziolko; Lisa A Weissfeld; William E Klunk; Chester A Mathis; Jessica A Hoge; Brian J Lopresti; Steven T DeKosky; Julie C Price Journal: Neuroimage Date: 2006-08-14 Impact factor: 6.556
Authors: Nora D Volkow; Gene-Jack Wang; Frank Telang; Joanna S Fowler; David Alexoff; Jean Logan; Millard Jayne; Christopher Wong; Dardo Tomasi Journal: Proc Natl Acad Sci U S A Date: 2014-07-14 Impact factor: 11.205
Authors: Jason P Connor; Daniel Stjepanović; Bernard Le Foll; Eva Hoch; Alan J Budney; Wayne D Hall Journal: Nat Rev Dis Primers Date: 2021-02-25 Impact factor: 52.329
Authors: Felicia Kamp; Lisa Proebstl; Nora Penzel; Kristina Adorjan; Andrej Ilankovic; Oliver Pogarell; Gabi Koller; Michael Soyka; Peter Falkai; Nikolaos Koutsouleris; Joseph Kambeitz Journal: Neuropsychopharmacology Date: 2018-08-27 Impact factor: 7.853
Authors: William S John; Thomas J Martin; Kiran Kumar Solingapuram Sai; Susan H Nader; H Donald Gage; Akiva Mintz; Michael A Nader Journal: J Pharmacol Exp Ther Date: 2017-12-04 Impact factor: 4.030
Authors: Andrew D Plunk; Arpana Agrawal; Paul T Harrell; William F Tate; Kelli England Will; Jennifer M Mellor; Richard A Grucza Journal: Drug Alcohol Depend Date: 2016-10-11 Impact factor: 4.492